60 related articles for article (PubMed ID: 6373316)
1. Long-term improvement in metabolic control of unstable type I diabetes by s.c. insulin injection patterns based on the dose profiles required by bed-side artificial beta-cell.
Bombor H; Bruns W; Ratzmann KP; Jutzi E; Albrecht G; Michaelis D; Fischer U
Exp Clin Endocrinol; 1984 Apr; 83(2):143-51. PubMed ID: 6373316
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of intensified insulin therapy.
Brunetti P; Bueti A; Antonella MA; Calabrese G; Fabietti PG; Santeusanio F; Massi Benedetti M
Exp Clin Endocrinol; 1984 Apr; 83(2):130-5. PubMed ID: 6373314
[TBL] [Abstract][Full Text] [Related]
3. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
4. Use of a glucose-controlled insulin infusion system in children and adolescents with insulin-dependent diabetes.
Golden MP; Myers GL; Tanner SM; Marrero DG; Charles MA
Pediatrics; 1982 Jul; 70(1):36-42. PubMed ID: 7088631
[TBL] [Abstract][Full Text] [Related]
5. Improvement of artificial endocrine pancreas (Biostator; GCIIS) performance combining feedback controlled insulin administration with a pre-programmed insulin infusion.
Calabrese G; Bueti A; Zega G; Giombolini A; Bellomo G; Antonella MA; Massi-Benedetti M; Brunetti P
Horm Metab Res; 1982 Oct; 14(10):505-7. PubMed ID: 6757081
[TBL] [Abstract][Full Text] [Related]
6. [Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin].
Petkova M; Khristov V; Tsanev A
Vutr Boles; 1990; 29(1):74-7. PubMed ID: 2204207
[TBL] [Abstract][Full Text] [Related]
7. Does an insulin pen improve the metabolic control of type 1 diabetes mellitus if added to conventional treatment?
Roos AN; Meinders AE
Neth J Med; 1989 Apr; 34(3-4):116-25. PubMed ID: 2657451
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
Hildebrandt P
Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy.
Christiansen JS; Svendsen PA; Mathiesen E; Rubin P; Deckert T
Horm Metab Res; 1981 Oct; 13(10):537-41. PubMed ID: 7028586
[TBL] [Abstract][Full Text] [Related]
10. Methods and effects of improved conventional insulin treatment in labile insulin-dependent diabetes (IDDM).
Menzel R; Brunstein U; Conde N; Bombor H; Albrecht G; Jutzi E
Exp Clin Endocrinol; 1984 Apr; 83(2):152-60. PubMed ID: 6373317
[TBL] [Abstract][Full Text] [Related]
11. A comparison of premeal subcutaneous insulin infusion and injection in type I diabetic patients under continuous basal subcutaneous insulin delivery.
Navascués I; Kerner W; Pfeiffer EF
Life Support Syst; 1985; 3(3):263-7. PubMed ID: 3900596
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
13. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
14. [Risks and side effects of intensified insulin therapy].
Honegger R; Spinas GA
Wien Med Wochenschr; 1997; 147(9):226-30. PubMed ID: 9281237
[TBL] [Abstract][Full Text] [Related]
15. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
16. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
Christiansen JS; Svendsen PA; Deckert T
Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
Stavljenić A; Granić M; Topić B; Skrabalo Z
Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
[TBL] [Abstract][Full Text] [Related]
18. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
Schernthaner G; Kopp HP; Ristic S; Muzyka B; Peter L; Mitteregger G
Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of unstable diabetes with a portable insulin-infusion pump (author's transl)].
Talaulicar M; Willms B
Dtsch Med Wochenschr; 1982 Mar; 107(11):419-23. PubMed ID: 7037348
[TBL] [Abstract][Full Text] [Related]
20. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
